Eliem acquires Tenet Medicines and with it TNT 119 a potential treatment for SLE.
Eliem Therapeutics, Inc.and Tenet Medicines, Inc. a development-stage private biotechnology company, announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.
The combined company plans to focus on advancing TNT 119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy. After closing of the transaction, the strategy of the combined company will be to develop TNT 119 for a range of autoimmune-mediated diseases, where we believe CD19-targeted approaches have clear biological rationale, where the combined company can potentially achieve clinical proof-of-concept, and where the combined company can introduce product candidates that can be meaningfully differentiated in the market. TNT 119’s lead indication is in systemic lupus erythematosus, the most common type of lupus and an autoimmune disease in which the immune system attacks its own tissue causing widespread inflammation and tissue damage in affected organs including joints, skin, brain, lungs kidneys and blood vessels.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins